Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.160.7NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.43.2 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.43.2 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.5NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.258.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.258.5NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.33NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.33NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.326NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.326NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.255NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.255NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.303NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.303NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AA.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
AA.7NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.173NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.173NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.309NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.309NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.105NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.105NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.1.8NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.1.8NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.11NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.11NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.258.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.258.7NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.307NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.307NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GK.2.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GK.2.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.20NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.20NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.7NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-6672.85US
B.1.177.6NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.560NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-6672.85US
B.1.560NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.610NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17890.7US
B.1.610NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.10 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.10 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.286NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.286NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.36.17NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used